Literature DB >> 10412819

Long-term follow up of a new case of hawkinsinuria.

W Lehnert1, W Stögmann, U Engelke, R A Wevers, G B van den Berg.   

Abstract

UNLABELLED: Hawkinsinuria is a rarely diagnosed autosomal dominantly transmitted inborn error of tyrosine metabolism with impaired conversion of 4-hydroxyphenylpyruvate to homogentisate. As a consequence of the defective 4-hydroxyphenylpyruvate dioxigenase activity, large amounts of the unusual, ninhydrin-positive amino acid hawkinsin and later on in life 4-hydroxycyclohexylacetic acid are formed and excreted. Clinically the disease is characterised mainly by chronic metabolic acidosis and severe growth retardation as a result of protein overload. As the ability to form 4-hydroxycyclohexylacetic acid and thereby to cope with the still not very well defined reactive and toxic intermediates increases, clinical symptoms vanish. We report here a new patient with hawkinsinuria having experienced a series of admissions because of unclear hepatopathy, growth retardation, and renal tubular acidosis.
CONCLUSION: Prolonged tyrosyluria in the newborn and young baby should cause the clinical chemist not only to exclude tyrosinaemia, galactosaemia, and fructose intolerance but also to look carefully for hawkinsin in the aminoacid chromatogram.

Entities:  

Mesh:

Substances:

Year:  1999        PMID: 10412819     DOI: 10.1007/s004310051151

Source DB:  PubMed          Journal:  Eur J Pediatr        ISSN: 0340-6199            Impact factor:   3.183


  2 in total

1.  Expanding the phenotype of hawkinsinuria: new insights from response to N-acetyl-L-cysteine.

Authors:  Natalia Gomez-Ospina; Anna I Scott; Gia J Oh; Donald Potter; Veena V Goel; Lauren Destino; Nancy Baugh; Gregory M Enns; Anna-Kaisa Niemi; Tina M Cowan
Journal:  J Inherit Metab Dis       Date:  2016-08-03       Impact factor: 4.982

Review 2.  Hawkinsinuria clinical practice guidelines: a Mexican case report and literature review.

Authors:  Héctor Cruz-Camino; Diana Laura Vazquez-Cantu; Alexandra Vanessa Zea-Rey; Jaime López-Valdez; Jorge Jiménez-Lozano; René Gómez-Gutiérrez; Consuelo Cantú-Reyna
Journal:  J Int Med Res       Date:  2019-07-25       Impact factor: 1.671

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.